Approved indications are a second or higher relapse or refractory disease of CD19+ BCP-ALL in patients ≤ 25 years of age (US and Europe) and any relapse post HSCT (Europe only) (Figure 2). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.